Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial
Samer Gawrieh, Mazen Noureddin, Nicole Loo, et al.
Hepatology (2021) Vol. 74, Iss. 4, pp. 1809-1824
Open Access | Times Cited: 265

Showing 1-25 of 265 citing articles:

Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Jun Guo, Xiuqing Huang, Lin Dou, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 700
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 314
Targeting fibrosis: mechanisms and clinical trials
Manyu Zhao, Liqun Wang, Mengzhu Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 252
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 203
Current treatment of non‐alcoholic fatty liver disease
Rafael Paternostro, Michael Trauner
Journal of Internal Medicine (2022) Vol. 292, Iss. 2, pp. 190-204
Open Access | Times Cited: 174
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 4, pp. 367-378
Open Access | Times Cited: 171
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
Chander K. Negi, Pavel Babica, Lola Bajard, et al.
Metabolism (2021) Vol. 126, pp. 154925-154925
Open Access | Times Cited: 163
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong Li, Junyan Zou, Wei Ran, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 152
Novel therapeutic targets for cholestatic and fatty liver disease
Michael Trauner, Claudia Fuchs
Gut (2021) Vol. 71, Iss. 1, pp. 194-209
Open Access | Times Cited: 133
New targets for NAFLD
Lucia Parlati, Marion Régnier, Hervé Guillou, et al.
JHEP Reports (2021) Vol. 3, Iss. 6, pp. 100346-100346
Open Access | Times Cited: 127
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Hao Chen, Huabing Tan, Juan Wan, et al.
Pharmacology & Therapeutics (2023) Vol. 245, pp. 108391-108391
Closed Access | Times Cited: 113
Breakthroughs in therapies for NASH and remaining challenges
Vlad Ratziu, Sven Francque, Arun J. Sanyal
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1263-1278
Open Access | Times Cited: 105
Reactive Oxygen Species Induce Fatty Liver and Ischemia-Reperfusion Injury by Promoting Inflammation and Cell Death
Shen-ping Tang, Xin‐Li Mao, Yahong Chen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 101
PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH)
Simona Todisco, Anna Santarsiero, Paolo Convertini, et al.
Biology (2022) Vol. 11, Iss. 5, pp. 792-792
Open Access | Times Cited: 76
Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease
Tobias Puengel, Hanyang Liu, Adrien Guillot, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2668-2668
Open Access | Times Cited: 74
Clinical Trial Landscape in NASH
Stephen A. Harrison, Rohit Loomba, Julie Dubourg, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2001-2014
Closed Access | Times Cited: 74
Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment
Paloma Sangro, Manuel de la Torre‐Aláez, Bruno Sangro, et al.
Journal of Physiology and Biochemistry (2023) Vol. 79, Iss. 4, pp. 869-879
Open Access | Times Cited: 66
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 59
NAFLD and NASH: etiology, targets and emerging therapies
Shulin Wei, Li Wang, Paul C. Evans, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 3, pp. 103910-103910
Closed Access | Times Cited: 57
NASH drug treatment development: challenges and lessons
Herbert Tilg, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 10, pp. 943-954
Open Access | Times Cited: 48
Treating NASH by targeting peroxisome proliferator-activated receptors
Bart Staels, Laura Butruille, Sven Francque
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1302-1316
Open Access | Times Cited: 44
The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease
Ilias D. Vachliotis, Stergios A. Pοlyzos
Current Obesity Reports (2023) Vol. 12, Iss. 3, pp. 191-206
Open Access | Times Cited: 42
Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis
Tracey G. Simon, Robert M. Wilechansky, Stefania Stoyanova, et al.
JAMA (2024) Vol. 331, Iss. 11, pp. 920-920
Open Access | Times Cited: 39
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Maximilian Huttasch, Michael Roden, S. Kahl
Metabolism (2024) Vol. 157, pp. 155937-155937
Open Access | Times Cited: 35
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 31
Page 1 - Next Page

Scroll to top